Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + (E)-5-(2-bromovinyl)-2'-deoxyuridine
?
Herpes simplex virus
-
Substrates: -
Products: -
?
ATP + (E)-5-(2-bromovinyl)-2'-deoxyuridine
ADP + (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate
ATP + 1-(beta-D-arabinofuranosyl)thymine
ADP + 1-(beta-D-arabinofuranosyl)thymine 5'-phosphate
ATP + 1-beta-D-arabinofuranosylthymine
ADP + 1-beta-D-arabinofuranosylthymine 5'-phosphate
-
Substrates: as active as with 2'-deoxythymidine
Products: -
?
ATP + 2',3'-didehydro-2',3'-dideoxythymidine
ADP + 2',3'-didehydro-2',3'-dideoxythymidine 5'-phosphate
-
Substrates: 12% activity compared to thymidine
Products: -
?
ATP + 2',3'-dideoxy-2',3'-didehydrothymidine
ADP + 2',3'-dideoxy-2',3'-didehydrothymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2',3'-dideoxy-3'-azidothymidine
ADP + 2',3'-dideoxy-3'-azidothymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2',3'-dideoxycytidine
ADP + 2',3'-dideoxycytidine 5'-phosphate
ATP + 2',3'-dideoxydehydrothymidine
ADP + 2',3'-dideoxydehydrothymidine 5'-phosphate
ATP + 2',3'-dideoxythymidine
ADP + 2',3'-dideoxythymidine 5'-phosphate
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
ATP + 2'-deoxyuridine
ADP + 2'-deoxyuridine 5'-phosphate
ATP + 2'-exo-methanocarba-thymidine
ADP + 2'-exo-methanocarba-thymidine 5'-monophosphate
Herpes simplex virus
-
Substrates: MCT
Products: -
?
ATP + 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil
ADP + 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil 5'-phosphate
Substrates: -
Products: -
?
ATP + 3'-(4-(2-phenylethyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(2-phenylethyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine 5'-phosphate
ATP + 3'-(4-(2-pyridine)-1,2,3-triazole-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(2-pyridine)-1,2,3-triazole-1-yl)-3'-deoxythymidine 5'-phosphate
ATP + 3'-(4-(3-chloropropyl)-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(3-chloropropyl)-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
ATP + 3'-(4-(4-fluorophenyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(4-fluorophenyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine 5'-phosphate
ATP + 3'-(4-benzyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-benzyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
ATP + 3'-(4-pentyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-pentyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
ATP + 3'-(4-phenyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-phenyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
ATP + 3'-(4-propyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-propyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
ATP + 3'-(4-tert-butyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-tert-butyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
ATP + 3'-azido-2',3'-deoxythymidine
ADP + 3'-azido-2',3'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 3'-azido-2',3'-dideoxythymidine
ADP + 3'-azido-2',3'-dideoxythymidine 5'-phosphate
ATP + 3'-azido-3'-deoxythymidine
ADP + 3'-azido-3'-deoxythymidine 5'-phosphate
ATP + 3'-azidothymidine
?
Herpes simplex virus
-
Substrates: -
Products: -
?
ATP + 3'-deoxy-2',3'-didehydro-thymidine
ADP + 3'-deoxy-2',3'-didehydro-thymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 3'-deoxy-2',3'-didehydrothymidine
ADP + 3'-deoxy-2',3'-didehydrothymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 3'-deoxythymidine
ADP + 3'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 3'-fluoro-3'-deoxythymidine
ADP + 3'-fluoro-3'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 3-(benzylcarbamimidoyl)thymidine
ADP + 3-(benzylcarbamimidoyl)thymidine 5'-phosphate
-
Substrates: 14.9% activity compared to thymidine
Products: -
?
ATP + 3-(butylcarbamimidoyl)thymidine
ADP + 3-(butylcarbamimidoyl)thymidine 5'-phosphate
-
Substrates: 1.2% activity compared to thymidine
Products: -
?
ATP + 3-(phenylcarbamimidoyl)thymidine
ADP + 3-(phenylcarbamimidoyl)thymidine 5'-phosphate
-
Substrates: 1.9% activity compared to thymidine
Products: -
?
ATP + 3-(tetrazol-5-ylmethyl)thymidine
ADP + 3-(tetrazol-5-ylmethyl)thymidine 5'-phosphate
-
Substrates: 39.5% activity compared to thymidine
Products: -
?
ATP + 3-[1(2)-closo-1,7-carboranylbutyltetrazol-5-ylmethyl]thymidine
ADP + 3-[1(2)-closo-1,7-carboranylbutyltetrazol-5-ylmethyl]thymidine 5'-phosphate
-
Substrates: 63.7% activity compared to thymidine
Products: -
?
ATP + 3-[1(2)-closo-1,7-carboranylbutyltetrazol-5-yl]thymidine
ADP + 3-[1(2)-closo-1,7-carboranylbutyltetrazol-5-yl]thymidine 5'-phosphate
-
Substrates: 42.5% activity compared to thymidine
Products: -
?
ATP + 3-[1(2)-closo-1,7-carboranylethyltetrazol-5-ylmethyl]thymidine
ADP + 3-[1(2)-closo-1,7-carboranylethyltetrazol-5-ylmethyl]thymidine 5'-phosphate
-
Substrates: 52.4% activity compared to thymidine
Products: -
?
ATP + 3-[1(2)-closo-1,7-carboranylethyltetrazol-5-yl]thymidine
ADP + 3-[1(2)-closo-1,7-carboranylethyltetrazol-5-yl]thymidine 5'-phosphate
-
Substrates: 55.6% activity compared to thymidine
Products: -
?
ATP + 3-[1(2)-closo-1,7-carboranylpropyltetrazol-5-ylmethyl]thymidine
ADP + 3-[1(2)-closo-1,7-carboranylpropyltetrazol-5-ylmethyl]thymidine 5'-phosphate
-
Substrates: 58.2% activity compared to thymidine
Products: -
?
ATP + 3-[1(2)-closo-1,7-carboranylpropyltetrazol-5-yl]thymidine
ADP + 3-[1(2)-closo-1,7-carboranylpropyltetrazol-5-yl]thymidine 5'-phosphate
-
Substrates: 42.9% activity compared to thymidine
Products: -
?
ATP + 3-[1(2)-propyltetrazol-5-ylmethyl]thymidine
ADP + 3-[1(2)-propyltetrazol-5-ylmethyl]thymidine 5'-phosphate
-
Substrates: 55.7% activity compared to thymidine
Products: -
?
ATP + 3-[1(2)-propyltetrazol-5-yl]thymidine
ADP + 3-[1(2)-propyltetrazol-5-yl]thymidine 5'-phosphate
-
Substrates: 57.6% activity compared to thymidine
Products: -
?
ATP + 3-[2-(closo-1,7-carboranyl)ethylcarbamimidoyl]thymidine
ADP + 3-[2-(closo-1,7-carboranyl)ethylcarbamimidoyl]thymidine 5'-phosphate
-
Substrates: 16.3% activity compared to thymidine
Products: -
?
ATP + 3-[2-imino-2-(benzylamino)ethyl]thymidine
ADP + 3-[2-imino-2-(benzylamino)ethyl]thymidine 5'-phosphate
-
Substrates: 16.8% activity compared to thymidine
Products: -
?
ATP + 3-[2-imino-2-(butylamino)ethyl]thymidine
ADP + 3-[2-imino-2-(butylamino)ethyl]thymidine 5'-phosphate
-
Substrates: 2.3% activity compared to thymidine
Products: -
?
ATP + 3-[2-imino-2-(phenylamino)ethyl]thymidine
ADP + 3-[2-imino-2-(phenylamino)ethyl]thymidine 5'-phosphate
-
Substrates: 11.3% activity compared to thymidine
Products: -
?
ATP + 3-[2-imino-2-(propylamino)ethyl]thymidine
ADP + 3-[2-imino-2-(propylamino)ethyl]thymidine 5'-phosphate
-
Substrates: 1.9% activity compared to thymidine
Products: -
?
ATP + 3-[2-imino-2-[2-(closo-1,7-carboranyl)ethylamino]ethyl]thymidine
ADP + 3-[2-imino-2-[2-(closo-1,7-carboranyl)ethylamino]ethyl]thymidine 5'-phosphate
-
Substrates: 3.0% activity compared to thymidine
Products: -
?
ATP + 3-[2-imino-2-[2-(closo-1,7-carboranyl)propylamino]ethyl]thymidine
ADP + 3-[2-imino-2-[2-(closo-1,7-carboranyl)propylamino]ethyl]thymidine 5'-phosphate
-
Substrates: 5.6% activity compared to thymidine
Products: -
?
ATP + 3-[3-(closo-1,7-carboranyl)propylcarbamimidoyl]thymidine
ADP + 3-[3-(closo-1,7-carboranyl)propylcarbamimidoyl]thymidine 5'-phosphate
-
Substrates: 15.5% activity compared to thymidine
Products: -
?
ATP + 3-[4-(closo-1,7-carboranyl)butylcarbamimidoyl]thymidine
ADP + 3-[4-(closo-1,7-carboranyl)butylcarbamimidoyl]thymidine 5'-phosphate
-
Substrates: 27.3% activity compared to thymidine
Products: -
?
ATP + 5-azido-3'-azido-2',3'-dideoxyuridine
ADP + 5-azido-3'-azido-2',3'-dideoxyuridine 5'-monophosphate
Herpes simplex virus
-
Substrates: -
Products: photoaffinity analog of 3'-azidothymidine
?
ATP + 5-bromo-2'-deoxyuridine
ADP + 5-bromo-2'-deoxyuridine 5'-phosphate
ATP + 5-bromodeoxyuridine
ADP + 5-bromodeoxyuridine 5'-phosphate
-
Substrates: 84% activity compared to thymidine
Products: -
?
ATP + 5-chloro-2'-deoxyuridine
ADP + 5-chloro-2'-deoxyuridine 5'-phosphate
ATP + 5-chlorodeoxyuridine
ADP + 5-chlorodeoxyuridine 5'-phosphate
-
Substrates: 110% activity compared to thymidine
Products: -
?
ATP + 5-diaza-2'-deoxyuridine
ADP + 5-diaza-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
ATP + 5-fluorodeoxyuridine
ADP + 5-fluorodeoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-hydroxymethyl-2'-deoxyuridine
ADP + 5-hydroxymethyl-2'-deoxyuridine 5'-phosphate
Substrates: -
Products: -
?
ATP + 5-iodo-2'-deoxyuridine
?
Substrates: 5-iodo-2'-deoxyuridine is efficiently phosphorylated by thymidine kinase confirming that these compound enters the active site of the enzyme and acts as alternate substrate
Products: -
?
ATP + 5-iodo-2'-deoxyuridine
ADP + 5-iodo-2'-deoxyuridine 5'-phosphate
ATP + 5-iododeoxyuridine
ADP + 5-iododeoxyuridine 5'-phosphate
-
Substrates: 89% activity compared to thymidine
Products: -
?
ATP + 5-mercapto-2'-deoxyuridine
ADP + 5-mercapto-2'-deoxyuridine 5'-phosphate
-
Substrates: ATP as phosphate donor can be replaced by dGTP, dATP, dCTP, GTP, and ITP
Products: -
?
ATP + 5-trifluoromethyl-2'-deoxyuridine
ADP + 5-trifluoromethyl-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-trifluoromethyl-2-deoxyuridine
?
Substrates: 5-trifluoromethyl-2-deoxyuridine is efficiently phosphorylated by thymidine kinase confirming that these compound enters the active site of the enzyme and acts as alternate substrate
Products: -
?
ATP + 6-aza-2'-deoxythymidine
ADP + 6-aza-2'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 9-(1,3-dihydroxy-2-propoxymethyl)guanine
ADP + 9-(1,3-dihydroxy-2-propoxymethyl)guanine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 9-[(hydroxyethoxy)methyl]guanine
ADP + 9-[(hydroxyethoxy)methyl]guanine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + aciclovir
ADP + aciclovir 5'-phosphate
-
Substrates: -
Products: -
?
ATP + aciclovir monophosphate
?
Herpes simplex virus
-
Substrates: -
Products: -
?
ATP + acyclovir
ADP + acyclovir 5'-phosphate
-
Substrates: -
Products: -
?
ATP + acyclovir
ADP + acyclovir phosphate
ATP + arabinosyl cytosine
?
Substrates: -
Products: -
?
ATP + azidothymidine
?
Substrates: -
Products: -
?
ATP + azidothymidine monophosphate
?
Substrates: -
Products: -
?
ATP + beta-5-ethyl-2'-deoxyuridine
?
Substrates: beta-5-ethyl-2'-deoxyuridine is efficiently phosphorylated by thymidine kinase confirming that these compound enters the active site of the enzyme and acts as alternate substrate
Products: -
?
ATP + beta-L-2',3'-dideoxy-3'-thiacytidine
ADP + beta-L-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
ATP + beta-L-thymidine
ADP + beta-L-thymidine 5'-phosphate
-
Substrates: less than 5% activity compared to thymidine
Products: -
?
ATP + cytosine arabinoside 5'-triphosphate
ADP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + deoxyadenosine
ADP + dAMP
ATP + deoxycytidine
ADP + dCMP
ATP + deoxyguanosine
ADP + dGMP
ATP + deoxyinosine
ADP + dIMP
ATP + deoxythymidine
ADP + dTMP
-
Substrates: ATP as phosphate donor can be replaced by dGTP, dATP, dCTP, GTP, and ITP
Products: -
?
ATP + deoxyuridine
ADP + dUMP
ATP + dideoxyinosine
ADP + dideoxyinosine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + difluorodeoxycytidine
?
Substrates: -
Products: -
?
ATP + difluorodeoxyuridine
?
Substrates: -
Products: -
?
ATP + dioxolane thymidine
ADP + dioxolane thymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + ganciclovir
?
Herpes simplex virus
-
Substrates: -
Products: -
?
ATP + ganciclovir
ADP + ganciclovir phosphate
-
Substrates: -
Products: -
?
ATP + ganciclovir monophosphate
?
Herpes simplex virus
-
Substrates: -
Products: -
?
ATP + guanosine
ADP + GMP
-
Substrates: 1% activity compared to thymidine
Products: -
?
ATP + iododeoxyuridine
ADP + iododeoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + lobucavir
?
Herpes simplex virus
-
Substrates: -
Products: -
?
ATP + methylthymidine
ADP + methylthymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
ATP + thymidine
ADP + thymidine 5'-phosphate
ATP + thymidine 5'-phosphate
ADP + thymidine diphosphate
Herpes simplex virus type 4
-
Substrates: -
Products: -
r
ATP + trifluoromethylthymidine
ADP + trifluoromethylthymidine 5-phosphate
-
Substrates: good substrate, 130% activity compared to thymidine
Products: -
?
ATP + uridine
ADP + UMP
-
Substrates: -
Products: -
?
ATP + uridine
ADP + uridine 5'-phosphate
Substrates: -
Products: -
?
ATP + [methyl-3H]thymidine
ADP + [methyl-3H]thymidine 5'-phosphate
-
Substrates: -
Products: -
?
CTP + thymidine
CDP + dTMP
-
Substrates: -
Products: -
?
CTP + thymidine
CDP + thymidine 5'-phosphate
dGTP + thymidine
dGDP + dTMP
-
Substrates: 99% activity compared to ATP
Products: -
?
GTP + thymidine
GDP + dTMP
GTP + thymidine
GDP + thymidine 5'-phosphate
TTP + thymidine
TDP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
UTP + thymidine
UDP + dTMP
additional information
?
-
ATP + (E)-5-(2-bromovinyl)-2'-deoxyuridine
ADP + (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate
-
Substrates: about 115% of the activity with 2'-deoxythymidine
Products: -
?
ATP + (E)-5-(2-bromovinyl)-2'-deoxyuridine
ADP + (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + (E)-5-(2-bromovinyl)-2'-deoxyuridine
ADP + (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + (E)-5-(2-bromovinyl)-2'-deoxyuridine
ADP + (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + (E)-5-(2-bromovinyl)-2'-deoxyuridine
ADP + (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-phosphate
-
Substrates: drug activation by phosphorylation
Products: -
?
ATP + 1-(beta-D-arabinofuranosyl)thymine
ADP + 1-(beta-D-arabinofuranosyl)thymine 5'-phosphate
Substrates: -
Products: -
?
ATP + 1-(beta-D-arabinofuranosyl)thymine
ADP + 1-(beta-D-arabinofuranosyl)thymine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2',3'-dideoxycytidine
ADP + 2',3'-dideoxycytidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2',3'-dideoxycytidine
ADP + 2',3'-dideoxycytidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2',3'-dideoxydehydrothymidine
ADP + 2',3'-dideoxydehydrothymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2',3'-dideoxydehydrothymidine
ADP + 2',3'-dideoxydehydrothymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2',3'-dideoxythymidine
ADP + 2',3'-dideoxythymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2',3'-dideoxythymidine
ADP + 2',3'-dideoxythymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
Herpes simplex virus
-
Substrates: -
Products: -
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
Substrates: -
Products: -
ir
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
Substrates: -
Products: -
ir
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
Substrates: induction of conformational changes upon ligand binding, overview
Products: -
ir
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
ir
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
Substrates: -
Products: -
ir
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
Substrates: -
Products: -
ir
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
Substrates: induction of conformational changes upon ligand binding, overview
Products: -
ir
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
ir
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2'-deoxythymidine
ADP + 2'-deoxythymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxyuridine
ADP + 2'-deoxyuridine 5'-phosphate
Herpes simplex virus
-
Substrates: -
Products: -
?
ATP + 2'-deoxyuridine
ADP + 2'-deoxyuridine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxyuridine
ADP + 2'-deoxyuridine 5'-phosphate
Substrates: -
Products: -
ir
ATP + 2'-deoxyuridine
ADP + 2'-deoxyuridine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxyuridine
ADP + 2'-deoxyuridine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxyuridine
ADP + 2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2'-deoxyuridine
ADP + 2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 2'-deoxyuridine
ADP + 2'-deoxyuridine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxyuridine
ADP + 2'-deoxyuridine 5'-phosphate
Substrates: -
Products: -
?
ATP + 2'-deoxyuridine
ADP + 2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 3'-(4-(2-phenylethyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(2-phenylethyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 2.4% activity compared to thymidine
Products: -
?
ATP + 3'-(4-(2-phenylethyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(2-phenylethyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 12.3% activity compared to thymidine
Products: -
?
ATP + 3'-(4-(2-pyridine)-1,2,3-triazole-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(2-pyridine)-1,2,3-triazole-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 3.1% activity compared to thymidine
Products: -
?
ATP + 3'-(4-(2-pyridine)-1,2,3-triazole-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(2-pyridine)-1,2,3-triazole-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 7.1% activity compared to thymidine
Products: -
?
ATP + 3'-(4-(3-chloropropyl)-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(3-chloropropyl)-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 2.7% activity compared to thymidine
Products: -
?
ATP + 3'-(4-(3-chloropropyl)-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(3-chloropropyl)-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 6.5% activity compared to thymidine
Products: -
?
ATP + 3'-(4-(4-fluorophenyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(4-fluorophenyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 2.6% activity compared to thymidine
Products: -
?
ATP + 3'-(4-(4-fluorophenyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
ADP + 3'-(4-(4-fluorophenyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 13.7% activity compared to thymidine
Products: -
?
ATP + 3'-(4-benzyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-benzyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 4.8% activity compared to thymidine
Products: -
?
ATP + 3'-(4-benzyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-benzyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 11.6% activity compared to thymidine
Products: -
?
ATP + 3'-(4-pentyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-pentyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 2.9% activity compared to thymidine
Products: -
?
ATP + 3'-(4-pentyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-pentyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 8.7% activity compared to thymidine
Products: -
?
ATP + 3'-(4-phenyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-phenyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 2.1% activity compared to thymidine
Products: -
?
ATP + 3'-(4-phenyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-phenyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 5.5% activity compared to thymidine
Products: -
?
ATP + 3'-(4-propyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-propyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 1.9% activity compared to thymidine
Products: -
?
ATP + 3'-(4-propyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-propyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 7.2% activity compared to thymidine
Products: -
?
ATP + 3'-(4-tert-butyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-tert-butyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 2.2% activity compared to thymidine
Products: -
?
ATP + 3'-(4-tert-butyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
ADP + 3'-(4-tert-butyl-1,2,3-triazol-1-yl)-3'-deoxythymidine 5'-phosphate
Substrates: 4.7% activity compared to thymidine
Products: -
?
ATP + 3'-azido-2',3'-dideoxythymidine
ADP + 3'-azido-2',3'-dideoxythymidine 5'-phosphate
-
Substrates: about 5% of the activity with 2'-deoxythymidine
Products: -
?
ATP + 3'-azido-2',3'-dideoxythymidine
ADP + 3'-azido-2',3'-dideoxythymidine 5'-phosphate
-
Substrates: 60% activity compared to thymidine
Products: -
?
ATP + 3'-azido-2',3'-dideoxythymidine
ADP + 3'-azido-2',3'-dideoxythymidine 5'-phosphate
-
Substrates: about 165% of the activity with 2'-deoxythymidine
Products: -
?
ATP + 3'-azido-3'-deoxythymidine
ADP + 3'-azido-3'-deoxythymidine 5'-phosphate
Q8LDP6, Q9FN47
Substrates: -
Products: -
?
ATP + 3'-azido-3'-deoxythymidine
ADP + 3'-azido-3'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 3'-azido-3'-deoxythymidine
ADP + 3'-azido-3'-deoxythymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 3'-azido-3'-deoxythymidine
ADP + 3'-azido-3'-deoxythymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 3'-azido-3'-deoxythymidine
ADP + 3'-azido-3'-deoxythymidine 5'-phosphate
Substrates: 47.3% activity compared to thymidine
Products: -
?
ATP + 3'-azido-3'-deoxythymidine
ADP + 3'-azido-3'-deoxythymidine 5'-phosphate
Substrates: -
Products: -
?
ATP + 3'-azido-3'-deoxythymidine
ADP + 3'-azido-3'-deoxythymidine 5'-phosphate
Substrates: 27.8% activity compared to thymidine
Products: -
?
ATP + 5-bromo-2'-deoxyuridine
ADP + 5-bromo-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-bromo-2'-deoxyuridine
ADP + 5-bromo-2'-deoxyuridine 5'-phosphate
-
Substrates: ATP as phosphate donor can be replaced by dGTP, dATP, dCTP, GTP, and ITP
Products: -
?
ATP + 5-bromo-2'-deoxyuridine
ADP + 5-bromo-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-bromo-2'-deoxyuridine
ADP + 5-bromo-2'-deoxyuridine 5'-phosphate
Substrates: -
Products: -
?
ATP + 5-bromo-2'-deoxyuridine
ADP + 5-bromo-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-bromo-2'-deoxyuridine
ADP + 5-bromo-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-chloro-2'-deoxyuridine
ADP + 5-chloro-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-chloro-2'-deoxyuridine
ADP + 5-chloro-2'-deoxyuridine 5'-phosphate
-
Substrates: ATP as phosphate donor can be replaced by dGTP, dATP, dCTP, GTP, and ITP
Products: -
?
ATP + 5-chloro-2'-deoxyuridine
ADP + 5-chloro-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
-
Substrates: good substrate, 120% activity compared to thymidine
Products: -
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
-
Substrates: ATP as phosphate donor can be replaced by dGTP, dATP, dCTP, GTP, and ITP
Products: -
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
Substrates: -
Products: -
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
Substrates: -
Products: -
?
ATP + 5-fluoro-2'-deoxyuridine
ADP + 5-fluoro-2'-deoxyuridine 5'-phosphate
Substrates: -
Products: -
?
ATP + 5-iodo-2'-deoxyuridine
ADP + 5-iodo-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-iodo-2'-deoxyuridine
ADP + 5-iodo-2'-deoxyuridine 5'-phosphate
-
Substrates: ATP as phosphate donor can be replaced by dGTP, dATP, dCTP, GTP, and ITP
Products: -
?
ATP + 5-iodo-2'-deoxyuridine
ADP + 5-iodo-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + 5-iodo-2'-deoxyuridine
ADP + 5-iodo-2'-deoxyuridine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + acyclovir
?
Herpes simplex virus
-
Substrates: -
Products: -
?
ATP + acyclovir
?
Herpes simplex virus
-
Substrates: poor substrate
Products: -
?
ATP + acyclovir
ADP + acyclovir phosphate
-
Substrates: drug activation by phosphorylation
Products: -
?
ATP + acyclovir
ADP + acyclovir phosphate
-
Substrates: drug activation by phosphorylation, some naturally occurring mutations lead to inability of acyclovir phosphorylation and thus resistance against the drug
Products: -
?
ATP + beta-L-2',3'-dideoxy-3'-thiacytidine
ADP + beta-L-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + beta-L-2',3'-dideoxy-3'-thiacytidine
ADP + beta-L-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + deoxyadenosine
ADP + dAMP
-
Substrates: -
Products: -
?
ATP + deoxyadenosine
ADP + dAMP
-
Substrates: -
Products: -
?
ATP + deoxycytidine
ADP + dCMP
-
Substrates: substrate for mutant enzymes M42I and L134A
Products: -
?
ATP + deoxycytidine
ADP + dCMP
-
Substrates: 7% activity compared to thymidine
Products: -
?
ATP + deoxycytidine
ADP + dCMP
-
Substrates: -
Products: -
?
ATP + deoxycytidine
ADP + dCMP
-
Substrates: -
Products: -
?
ATP + deoxycytidine
ADP + dCMP
-
Substrates: -
Products: -
?
ATP + deoxycytidine
ADP + dCMP
-
Substrates: -
Products: -
?
ATP + deoxyguanosine
ADP + dGMP
-
Substrates: substrate for mutant enzymes S182T and S182A
Products: -
?
ATP + deoxyguanosine
ADP + dGMP
-
Substrates: about 20% activity compared to thymidine
Products: -
?
ATP + deoxyguanosine
ADP + dGMP
-
Substrates: about 20% activity compared to thymidine
Products: -
?
ATP + deoxyinosine
ADP + dIMP
-
Substrates: about 30% activity compared to thymidine
Products: -
?
ATP + deoxyinosine
ADP + dIMP
-
Substrates: about 30% activity compared to thymidine
Products: -
?
ATP + deoxyuridine
ADP + dUMP
Q8LDP6, Q9FN47
Substrates: -
Products: -
?
ATP + deoxyuridine
ADP + dUMP
-
Substrates: 69% activity compared to thymidine
Products: -
?
ATP + deoxyuridine
ADP + dUMP
-
Substrates: ATP as phosphate donor can be replaced by dGTP, dATP, dCTP, GTP, and ITP
Products: -
?
ATP + deoxyuridine
ADP + dUMP
-
Substrates: about 185% activity compared to thymidine
Products: -
?
ATP + thymidine
?
-
Substrates: involved in DNA replication
Products: -
?
ATP + thymidine
?
-
Substrates: -
Products: -
?
ATP + thymidine
?
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Q8LDP6, Q9FN47
Substrates: best substrate
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dGTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dCTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dATP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by CTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: 100% activity
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by GTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dGTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: requirement for high levels of ATP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dATP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by CTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by ITP
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Herpes simplex virus
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Herpes simplex virus
-
Substrates: ATP can be substituted by GTP
Products: -
?
ATP + thymidine
ADP + dTMP
Herpes simplex virus
-
Substrates: ATP can be substituted by dGTP
Products: -
?
ATP + thymidine
ADP + dTMP
Herpes simplex virus
-
Substrates: ATP can be substituted by dCTP
Products: -
?
ATP + thymidine
ADP + dTMP
Herpes simplex virus
-
Substrates: ATP can be substituted by dATP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: 100% activity
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: 100% activity
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by GTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dGTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by UTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dCTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dATP
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: ATP can be substituted by CTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Murine gammaherpesvirus-68
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by GTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dGTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by ATP-arabinoside
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by UTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dCTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dATP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by GTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dGTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by UTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dATP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by GTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dGTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by UTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dCTP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by dATP
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: ATP can be substituted by CTP
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Tequatrovirus T4
-
Substrates: ATP can be substituted by dATP
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
-
Substrates: best substrate combination, 100% activity
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: 100% activity
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: -
Products: -
?
ATP + thymidine
ADP + dTMP
Substrates: pyrimidine salvage route
Products: -
?
ATP + thymidine
ADP + thymidine 5'-phosphate
Substrates: -
Products: -
ir
ATP + thymidine
ADP + thymidine 5'-phosphate
Substrates: ATP acts as specific phosphate donor
Products: -
?
ATP + thymidine
ADP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + thymidine 5'-phosphate
Herpes simplex virus type 4
-
Substrates: -
Products: -
r
ATP + thymidine
ADP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + thymidine 5'-phosphate
-
Substrates: enzyme contains the putative thymidine-binding motif FQRK
Products: -
?
ATP + thymidine
ADP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + thymidine 5'-phosphate
P03176
Substrates: -
Products: -
?
ATP + thymidine
ADP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
ATP + thymidine
ADP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
CTP + thymidine
CDP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
CTP + thymidine
CDP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
CTP + thymidine
CDP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
GTP + thymidine
GDP + dTMP
-
Substrates: 42% activity compared to ATP
Products: -
?
GTP + thymidine
GDP + dTMP
-
Substrates: -
Products: -
?
GTP + thymidine
GDP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
GTP + thymidine
GDP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
GTP + thymidine
GDP + thymidine 5'-phosphate
-
Substrates: -
Products: -
?
UTP + thymidine
UDP + dTMP
-
Substrates: 17% activity compared to ATP
Products: -
?
UTP + thymidine
UDP + dTMP
-
Substrates: -
Products: -
?
UTP + thymidine
UDP + dTMP
-
Substrates: -
Products: -
?
additional information
?
-
-
Substrates: the wild type enzyme shows no activity with deoxycytidine and deoxyadenosine
Products: -
?
additional information
?
-
-
Substrates: overview: phosphoryl donors
Products: -
?
additional information
?
-
-
Substrates: the type II thymidine kinase ecoded by cowpox virus exhibits a more limited substrate specificity than the type I thymidine kinase encoded by HSV-1
Products: -
?
additional information
?
-
-
Substrates: CTP, diphosphate, uridine, adenosine, cytosine, deoxyguanosine, deoxyguanosine, dTMP, thymine 1-beta-D-arabinofuranoside, 1-beta-D-arabinofuranosylcytosine, acyclovir, and 5-iodo-2'-deoxycytidine are no substrates
Products: -
?
additional information
?
-
Substrates: beta-L-thymidine is poorly phosphorylated by the enzyme
Products: -
?
additional information
?
-
-
Substrates: beta-L-thymidine is poorly phosphorylated by the enzyme
Products: -
?
additional information
?
-
Substrates: does not use UTP, GTP, and TTP as cosubstrates
Products: -
?
additional information
?
-
-
Substrates: does not use UTP, GTP, and TTP as cosubstrates
Products: -
?
additional information
?
-
-
Substrates: overview: thymidine analogs
Products: -
?
additional information
?
-
Herpes simplex virus type 4
-
Substrates: wide substrate specificity phosphorylating pyrimidine nucleosides, nucleoside monophophates, and several nucleoside analogues
Products: -
?
additional information
?
-
Substrates: the cell-cycle-regulated enzyme is important in nucleotide metabolism and an activator of antiviral and anticancer drugs
Products: -
?
additional information
?
-
-
Substrates: the cell-cycle-regulated enzyme is important in nucleotide metabolism and an activator of antiviral and anticancer drugs
Products: -
?
additional information
?
-
-
Substrates: the enzyme is tightly regulated in the cell cycle by multiple mechanism, e.g. by phosphorylation at Ser13 in mitotic-arrested cells, regulation model
Products: -
?
additional information
?
-
-
Substrates: ligand-induced conformational changes in dimeric and tetrameric forms of the enzyme alter the catalytic activity
Products: -
?
additional information
?
-
Substrates: narrow substrate specificity
Products: -
?
additional information
?
-
-
Substrates: narrow substrate specificity
Products: -
?
additional information
?
-
-
Substrates: Val106 has effects on structure-function relation of the enzyme
Products: -
?
additional information
?
-
-
Substrates: no activity with 3-(propylcarbamimidoyl)thymidine and 3-(tetrazol-5-yl)thymidine
Products: -
?
additional information
?
-
-
Substrates: the type II thymidine kinase ecoded by cowpox virus exhibits a more limited substrate specificity than the type I thymidine kinase encoded by HSV-1
Products: -
?
additional information
?
-
-
Substrates: overview thymine nucleosides, 2'-deoxyribonucleosides, arabinosides, ribonucleosides
Products: -
?
additional information
?
-
-
Substrates: the viral enzyme shows a broader substrate specificity than the human host cell enzyme
Products: -
?
additional information
?
-
-
Substrates: modeling of ganciclovir binding into the enzyme crystal structure, overview
Products: -
?
additional information
?
-
-
Substrates: no substrates: ganciclovir, acyclovir, 2'-deoxycytidine
Products: -
?
additional information
?
-
-
Substrates: substrate specificity of wild-type and mutant enzymes, overview
Products: -
?
additional information
?
-
Substrates: overview: nucleoside analogs
Products: -
?
additional information
?
-
-
Substrates: overview: nucleoside analogs
Products: -
?
additional information
?
-
-
Substrates: 5-halogenated cytidines, bromouridine, iodouridine, uridine, 5-fluorodeoxycytidine, purine ribonucleosides
Products: -
?
additional information
?
-
-
Substrates: comparison rat liver, Trypanosoma brucei
Products: -
?
additional information
?
-
Tequatrovirus T4
-
Substrates: no phosphorylation of deoxyuridine, 5-halogenated deoxyuridines
Products: -
?
additional information
?
-
Substrates: no activity with uridine, L-thymidine or 2',3'-dideoxyuridine
Products: -
?
additional information
?
-
-
Substrates: no activity with uridine, L-thymidine or 2',3'-dideoxyuridine
Products: -
?
additional information
?
-
Substrates: no activity with uridine, L-thymidine or 2',3'-dideoxyuridine
Products: -
?
additional information
?
-
-
Substrates: domain 1 of thymidine kinase is catalytically inactive but improves substrate binding by domain 2. The enzyme shows the following order of catalytic efficiencies: thymidine > deoxyuridine >> deoxyinosine > deoxyguanosine. The enzyme shows no activity with deoxyadenosine and deoxycytidine
Products: -
?
additional information
?
-
-
Substrates: comparison rat liver, Trypanosoma brucei
Products: -
?
additional information
?
-
-
Substrates: domain 1 of thymidine kinase is catalytically inactive but improves substrate binding by domain 2. The enzyme shows the following order of catalytic efficiencies: thymidine > deoxyuridine >> deoxyinosine > deoxyguanosine. The enzyme shows no activity with deoxyadenosine and deoxycytidine
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl 3,3-dimethylbutanoate
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl benzoate
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl diphenylacetate
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl dodecanoate
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl heptanoate
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl pivalate
(4E)-N-(diphenylmethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hex-4-enamide
(4E)-N-[cyano(phenyl)methyl]-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hex-4-enamide
(E)-5-(2-bromovinyl)-1-beta-D-(arabinofuranosyl)uracil
-
-
1-(3'-deoxy-5'-O-triphenylmethyl-beta-D-thymidin-3'-yl)-3-(4-chloro-3-(trifluoromethyl)-phenyl)-thiourea
-
-
1-(3,4-dichlorobenzyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
1-(3,4-dichlorophenyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
1-benzyl-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
1-beta-D-(arabinofuranosyl)thymine
-
-
1-[(2Z)-4-(4-benzylpiperazin-1-yl)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2Z)-4-(benzylamino)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2Z)-4-(benzyloxy)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2Z)-4-(dibenzylamino)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-5,6-dihydrothymine
1-[(2Z)-4-hydroxybut-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine
-
-
1-[2,3-dihydroxy-4-(trityloxy)butyl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[3-hydroxy-4-(trityloxy)butyl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(2S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]thiourea
1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(2S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]urea
1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
1-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]-3-phenylthiourea
2'-deoxy-3'-aminothymidine
-
5 mM
2'-exo-methanocarba-thymidine
Herpes simplex virus
-
-
2-(4-chlorophenyl)-N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]acetamide
2-biphenyl-4-yl-N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]acetamide
3'-(1,2,3-triazol-1-yl)-3'-deoxy-beta-D-thymidine
-
-
3'-(4-(2-phenyl-ethyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
3'-(4-(2-pyridine)-1,2,3-triazole-1-yl)-3'-deoxythymidine
3'-(4-(3-chloro-propyl)-1,2,3-triazol-1-yl)-3'-deoxythymidine
3'-(4-(4-fluorophenyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
3'-(4-benzyl-1,2,3-triazol-1-yl)-3'-deoxy-beta-D-thymidine
-
-
3'-(4-benzyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
3'-(4-butyl-1,2,3-triazol-1-yl)-3'-deoxy-beta-D-thymidine
-
-
3'-(4-chlorobenzylamino)-3'-deoxy-beta-D-thymidine
-
-
3'-(4-chlorophenyl-1,2,3-triazol-1-yl)-3'-deoxy-beta-(E)-5-(2-bromovinyl)-2'-deoxyuridine
-
-
3'-(4-chlorophenyl-1,2,3-triazol-1-yl)-3'-deoxy-beta-D-thymidine
-
-
3'-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-3'-deoxy-beta-D-thymidine
-
-
3'-(4-pentyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
3'-(4-phenyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
3'-(4-propyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
3'-(4-tert-butyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
3'-(5-(4-chlorophenyl)-1,2,3-triazol-1-yl)-3'-deoxy-beta-D-thymidine
-
-
3'-([[(4-chlorophenyl)carbamothioyl]amino]methyl)-3'-deoxythymidine
3'-([[4-chloro-3-(trifluoromethyl)phenyl]carbamothioyl]amino)-2',3'-dideoxy-3,4-dihydrothymidine
-
-
3'-azido-2',3'-dideoxy-3,4-dihydrothymidine
3'-azido-3'-deoxythymidine
3'-benzylamino-3'-deoxy-beta-D-thymidine
-
-
3'-deoxy-3'-(4-(3,4-dichlorophenyl)-1,2,3-triazol-1-yl)-beta-D-thymidine
-
-
3'-deoxy-3'-(4-phenyl-1,2,3-triazol-1-yl)-beta-(E)-5-(2-bromovinyl)-2'-deoxyuridine
-
-
3'-deoxy-3'-(4-phenyl-1,2,3-triazol-1-yl)-beta-D-thymidine
-
-
3'-deoxy-3'-(4-pyridin-2-yl-1,2,3-triazol-1-yl)-beta-D-thymidine
-
-
3'-deoxy-3'-(5-phenyl-1,2,3-triazol-1-yl)-beta-D-thymidine
-
-
3'-deoxy-3'-([[(3,4-dichlorophenyl)carbamothioyl]amino]methyl)thymidine
3'-deoxy-3'-([[(4-methoxyphenyl)carbamothioyl]amino]methyl)thymidine
3'-deoxy-3'-([[(4-methylphenyl)carbamothioyl]amino]methyl)thymidine
3'-deoxy-3'-fluorothymidine
-
inhibits thymidine phosphorylation catalyzed by thymidine kinase 2
3'-ethyl-5-methyl-2'-deoxyuridine
-
3'-fluorothymidine
-
inhibits thymidine phosphorylation catalyzed by thymidine kinase 2
3'-hexanoylamino-3'-deoxythymidine
-
very potent inhibitor of thymidine kinase 2
3'-O-ethyl-2'-deoxyuridine
-
3'-O-methyl-2'-deoxyuridine
-
3'-spiro-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)-5-methyluridine
inhibits phosphorylation of 2'-deoxythymidine, IC50: 0.0046 mM
3'-[(3-trifluoromethyl-4-chloro)-benzylamino]-3'-deoxy-beta-D-thymidine
-
-
3'-[([[4-(benzyloxy)phenyl]carbamothioyl]amino)methyl]-3'-deoxythymidine
3'-[([[4-chloro-3-(trifluoromethyl)phenyl]carbamothioyl]amino)methyl]-3'-deoxythymidine
3-N-methyl-5-iodo-2'-deoxyuridine
-
-
4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-tritylbutanamide
4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-[2-oxo-2-(tritylamino)ethyl]butanamide
5'-deoxy-5'-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamothioyl)amino]thymidine
5'-deoxy-5'-[[(diphenylmethyl)carbamothioyl]amino]thymidine
5'-O-(4,4'-dimethoxytrityl)thymidine
IC50: 0.468 mM
5'-O-[4-(fluorosulfonyl)benzene-1-sulfonyl]thymidine
-
-
5-(3'-amino-3'-deoxy-beta-(E)-5-(2-bromovinyl)-2'-deoxyuridin-3'Nyl)-1-(4-chloro-3-trifluoromethylphenyl)-tetrazole
-
-
5-(3'-amino-3'-deoxy-beta-D-thymidin-3'N-yl)-1-(4-chloro-3-trifluoromethylphenyl)-tetrazole
-
-
5-(3'-amino-3'-deoxy-beta-D-thymidin-3'N-yl)-1-benzyl-tetrazole
-
-
5-(E)-(2-bromovinyl)-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-uracil
5-(E)-(2-bromovinyl)uridine
5-azido-2'-deoxyuridine
Herpes simplex virus
-
50% photoincorporation inhibition of wild-type enzyme at 0.003 mM, 50% photoincorporation inhibition of C336Y mutant at 0.05 mM
5-azido-2'-deoxyuridine-5'-monophosphate
Herpes simplex virus
-
50% photoincorporation inhibition of wild-type enzyme at 0.05 mM, 50% photoincorporation inhibition of C336Y mutant at 0.135 mM
5-benzylamino-(3'-deoxy-beta-D-thymidin-3'N-yl)-tetrazole
-
-
5-bromovinyldeoxyuridine
Herpes simplex virus
-
50% photoincorporation inhibition of wild-type enzyme at 0.0015 mM, 50% photoincorporation inhibition of C336Y mutant above 0.025 mM
5-Chlorodeoxyuridine
-
competitive to thymidine
5-ethyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-uracil
5-fluoro-2'-deoxyuridine
concentration dependent reduction of activity
5-iodo-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-uracil
5-iodo-2'-deoxyuridine
potent inhibitor
5-methyl-1-[(2E)-4-(trityloxy)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
5-methyl-1-[(2Z)-4-(4-methylpiperazin-1-yl)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
5-methyl-1-[(2Z)-4-(tritylamino)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
5-methyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-cytosine
5-methyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
5-methyl-1-[4-(trityloxy)but-2-yn-1-yl]pyrimidine-2,4(1H,3H)-dione
5-methyl-1-[4-(trityloxy)butyl]pyrimidine-2,4(1H,3H)-dione
5-propyl-2'-deoxyuridine
-
5-trifluoromethyl-2-deoxyuridine
potent inhibitor
5-Trifluoromethyldeoxyuridine
-
competitive to thymidine
5-[(4-chloro-3-trifluoromethylphenyl)amino]-1-(3'-deoxy-beta-D-thymidin-3'N-yl)-tetrazole
-
-
5-[(E)-2-bromoethenyl]-2'-O-decanoyluridine
competitive with respect to 2'-deoxythymidine, IC50: 0.0012 mm
5-[(E)-2-bromoethenyl]-2'-O-octanoyluridine
5-[amino-(4-chloro-3-trifluoromethylphenyl)]-1-(3'-deoxy-beta-(E)-5-(2-bromovinyl)-2'-deoxyuridin-3'N-yl)-tetrazole
-
-
6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-tritylhexanamide
9-[(2Z)-4-(trityloxy)but-2-en-1-yl]-guanine
aciclovir
Herpes simplex virus
-
competitive inhibitor
acyclovir H-phosphonate
-
-
alpha-D-5-ethyl-2'-deoxyuridine
-
ammoniumsulfate
Herpes simplex virus
-
50% inhibition at 200 mM
beta-D-5-ethyl-2'-deoxyuridine
potent inhibitor
beta-L-thymidine
potent inhibitor
dATP
-
strong feedback inhibition, tight binding at the active site in stoichiometric amount
dGDP
-
competitive to ATP
EDTA
-
complete incactivation at 2.5 mM
iododeoxycytidine
Herpes simplex virus
-
-
Mg2+
Tequatrovirus T4
-
non-competitive
N-(2-cyanoethyl)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
N-(2-cyanoethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
N-(2-[[cyano(phenyl)methyl]amino]-2-oxoethyl)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
N-(3'-deoxy-beta-D-thymidin-3'-yl)-N'-(4-chloro-3-trifluoromethylphenyl)-benzylguanidine
-
-
N-(3'-deoxy-beta-D-thymidin-3'-yl)-N'-(4-chloro-3-trifluoromethylphenyl)-guanidine
-
-
N-(3'-deoxy-beta-D-thymidin-3'-yl)-N'-(4-chloro-3-trifluoromethylphenyl)-isopropylguanidine
-
-
N-(cyanomethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
N-(diphenylmethyl)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
N-(diphenylmethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
N-methyl-4-[[[8-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)octyl]oxy](diphenyl)methyl]benzamide
-
-
N-methyl-4-[{[8-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)octyl]oxy}(diphenyl)methyl]benzamide
-
-
N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]-2,2-diphenylacetamide
N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]-3-(trifluoromethyl)benzamide
N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]-9H-xanthene-9-carboxamide
N-[2-[(diphenylmethyl)amino]-2-oxoethyl]-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
N-[cyano(phenyl)methyl]-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
N-[cyano(phenyl)methyl]-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
N3-methyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-thymine
P1-(5'-adenosyl)-P5-(5'-thymidyl)pentaphosphate
-
P1-(Adenosine-5')-P3-(thymidine-5')-triphosphate
-
-
P1-(adenosine-5')-P4-(thymidine-5')-tetraphosphate
-
-
P1-(Adenosine-5')-P5-(thymidine-5')-pentaphosphate
-
-
P1-(Adenosine-5')-P6-(thymidine-5')-hexaphosphate
-
-
potassium phosphate
-
80% inhibition at 50 mM
sulfate
-
competitive inhibitor of ATP binding
thymidylate
Herpes simplex virus
-
50% photoincorporation inhibition of wild-type and C336Y mutant enzyme at 0.0125 mM
trifluridine
concentration dependent reduction of activity
W7
slight inhibitory in presence of calmodulin
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl 3,3-dimethylbutanoate
IC50: 0.028 mM
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl 3,3-dimethylbutanoate
-
IC50: above 0.5 mM
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl benzoate
IC50: 0.03 mM
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl benzoate
-
IC50: above 0.5 mM
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl diphenylacetate
IC50: 0.0046 mM
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl diphenylacetate
-
IC50: 0.281 mM
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl dodecanoate
IC50: 0.019 mM
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl dodecanoate
-
IC50: above 0.5 mM
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl heptanoate
IC50: 0.011 mM
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl heptanoate
-
IC50: 0.42 mM
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl pivalate
IC50: 0.04 mM
(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl pivalate
-
IC50: above 0.5 mM
(4E)-N-(diphenylmethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hex-4-enamide
IC50: 0.265 mM
(4E)-N-(diphenylmethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hex-4-enamide
-
IC50: above 0.5 mM
(4E)-N-[cyano(phenyl)methyl]-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hex-4-enamide
IC50: 0.371 mM
(4E)-N-[cyano(phenyl)methyl]-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hex-4-enamide
-
IC50: above 0.5 mM
1-(3,4-dichlorobenzyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
-
-
1-(3,4-dichlorobenzyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
P03176
-
1-(3,4-dichlorophenyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
-
-
1-(3,4-dichlorophenyl)-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
P03176
-
1-benzyl-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
-
-
1-benzyl-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
P03176
-
1-[(2Z)-4-(4-benzylpiperazin-1-yl)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
IC50: 0.18 mM
1-[(2Z)-4-(4-benzylpiperazin-1-yl)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
-
IC50: 0.18 mM
1-[(2Z)-4-(benzylamino)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
IC50: 0.057 mM
1-[(2Z)-4-(benzylamino)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
-
IC50: 0.057 mM
1-[(2Z)-4-(benzyloxy)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
IC50: 0.022 mM
1-[(2Z)-4-(benzyloxy)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
-
IC50: above 0.5 mM
1-[(2Z)-4-(dibenzylamino)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
IC50: 0.0035 mM; IC50: above 0.5 mM
1-[(2Z)-4-(dibenzylamino)but-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
-
IC50: 0.0035 mM
1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-5,6-dihydrothymine
IC50: 0.01 mM
1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-5,6-dihydrothymine
-
IC50: above 0.5 mM
1-[(2Z)-4-hydroxybut-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
IC50: 0.173 mM
1-[(2Z)-4-hydroxybut-2-en-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
-
IC50: 0.224 mM
1-[2,3-dihydroxy-4-(trityloxy)butyl]-5-methylpyrimidine-2,4(1H,3H)-dione
IC50: 0.017 mM
1-[2,3-dihydroxy-4-(trityloxy)butyl]-5-methylpyrimidine-2,4(1H,3H)-dione
-
IC50: 0.013 mM
1-[3-hydroxy-4-(trityloxy)butyl]-5-methylpyrimidine-2,4(1H,3H)-dione
IC50: 0.0036 mM
1-[3-hydroxy-4-(trityloxy)butyl]-5-methylpyrimidine-2,4(1H,3H)-dione
-
IC50: 0.0012 mM
1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(2S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]thiourea
-
-
1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(2S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]thiourea
P03176
-
1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(2S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]urea
-
-
1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(2S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl]urea
P03176
-
1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
-
-
1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]thiourea
P03176
-
1-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]-3-phenylthiourea
-
-
1-[[(2R,3S,5S)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl]-3-phenylthiourea
P03176
-
2-(4-chlorophenyl)-N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]acetamide
IC50: 0.023 mM
2-(4-chlorophenyl)-N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]acetamide
-
IC50: 0.198 mM
2-biphenyl-4-yl-N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]acetamide
IC50: 0.0041 mM
2-biphenyl-4-yl-N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]acetamide
-
IC50: 0.119 mM
3'-(4-(2-phenyl-ethyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
-
3'-(4-(2-phenyl-ethyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
-
3'-(4-(2-pyridine)-1,2,3-triazole-1-yl)-3'-deoxythymidine
-
3'-(4-(2-pyridine)-1,2,3-triazole-1-yl)-3'-deoxythymidine
-
3'-(4-(3-chloro-propyl)-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-(4-(3-chloro-propyl)-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-(4-(4-fluorophenyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
-
3'-(4-(4-fluorophenyl)-1,2,3-triazole-1-yl)-3'-deoxythymidine
-
3'-(4-benzyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-(4-benzyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-(4-pentyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-(4-pentyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-(4-phenyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-(4-phenyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-(4-propyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-(4-propyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-(4-tert-butyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-(4-tert-butyl-1,2,3-triazol-1-yl)-3'-deoxythymidine
-
3'-([[(4-chlorophenyl)carbamothioyl]amino]methyl)-3'-deoxythymidine
-
-
3'-([[(4-chlorophenyl)carbamothioyl]amino]methyl)-3'-deoxythymidine
P03176
-
3'-azido-2',3'-dideoxy-3,4-dihydrothymidine
-
inhibits thymidine phosphorylation catalyzed by thymidine kinase 2
3'-azido-2',3'-dideoxy-3,4-dihydrothymidine
-
inhibits thymidine phosphorylation catalyzed by thymidine kinase 2
3'-azido-3'-deoxythymidine
-
3'-azido-3'-deoxythymidine
-
3'-deoxy-3'-([[(3,4-dichlorophenyl)carbamothioyl]amino]methyl)thymidine
-
-
3'-deoxy-3'-([[(3,4-dichlorophenyl)carbamothioyl]amino]methyl)thymidine
P03176
-
3'-deoxy-3'-([[(4-methoxyphenyl)carbamothioyl]amino]methyl)thymidine
-
-
3'-deoxy-3'-([[(4-methoxyphenyl)carbamothioyl]amino]methyl)thymidine
P03176
-
3'-deoxy-3'-([[(4-methylphenyl)carbamothioyl]amino]methyl)thymidine
-
-
3'-deoxy-3'-([[(4-methylphenyl)carbamothioyl]amino]methyl)thymidine
P03176
-
3'-[([[4-(benzyloxy)phenyl]carbamothioyl]amino)methyl]-3'-deoxythymidine
-
-
3'-[([[4-(benzyloxy)phenyl]carbamothioyl]amino)methyl]-3'-deoxythymidine
P03176
-
3'-[([[4-chloro-3-(trifluoromethyl)phenyl]carbamothioyl]amino)methyl]-3'-deoxythymidine
-
-
3'-[([[4-chloro-3-(trifluoromethyl)phenyl]carbamothioyl]amino)methyl]-3'-deoxythymidine
P03176
-
4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-tritylbutanamide
IC50: 0.44 mM
4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-tritylbutanamide
-
IC50: 0.175 mM
4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-[2-oxo-2-(tritylamino)ethyl]butanamide
IC50: 0.194 mM
4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-[2-oxo-2-(tritylamino)ethyl]butanamide
-
IC50: 0.191 mM
5'-deoxy-5'-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamothioyl)amino]thymidine
-
-
5'-deoxy-5'-[(tricyclo[3.3.1.13,7]dec-1-ylcarbamothioyl)amino]thymidine
P03176
-
5'-deoxy-5'-[[(diphenylmethyl)carbamothioyl]amino]thymidine
-
-
5'-deoxy-5'-[[(diphenylmethyl)carbamothioyl]amino]thymidine
P03176
-
5-(E)-(2-bromovinyl)-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-uracil
IC50: 0.0013 mM; IC50: 0.1 mM
5-(E)-(2-bromovinyl)-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-uracil
-
IC50: above 0.5 mM
5-(E)-(2-bromovinyl)uridine
inhibits phosphorylation of 2'-deoxythymidine
5-(E)-(2-bromovinyl)uridine
-
-
5-bromodeoxyuridine
-
-
5-bromodeoxyuridine
-
competitive to thymidine
5-bromodeoxyuridine
-
competitive to thymidine
5-ethyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-uracil
IC50: 0.02 mM
5-ethyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-uracil
-
IC50: above 0.5 mM
5-fluorodeoxyuridine
-
-
5-fluorodeoxyuridine
-
competitive to thymidine
5-fluorodeoxyuridine
-
competitive to thymidine
5-iodo-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-uracil
IC50: 0.0046 mM
5-iodo-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-uracil
-
IC50: 0.048 mM
5-iododeoxyuridine
-
competitive to thymidine
5-iododeoxyuridine
-
competitive to thymidine
5-methyl-1-[(2E)-4-(trityloxy)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
IC50: 0.025 mM
5-methyl-1-[(2E)-4-(trityloxy)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
-
IC50: 0.003 mM
5-methyl-1-[(2Z)-4-(4-methylpiperazin-1-yl)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
IC50: 0.491 mM
5-methyl-1-[(2Z)-4-(4-methylpiperazin-1-yl)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
-
IC50: 0.491 mM
5-methyl-1-[(2Z)-4-(tritylamino)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
IC50: 0.0023 mM; IC50: above 0.5 mM
5-methyl-1-[(2Z)-4-(tritylamino)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
-
IC50: 0.0023 mM
5-methyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-cytosine
IC50: 0.484 mM
5-methyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-cytosine
-
IC50: above 0.5 mM
5-methyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
IC50: 0.0015 mM; IC50: above 0.1 mM
5-methyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]pyrimidine-2,4(1H,3H)-dione
-
IC50: 0.045 mM
5-methyl-1-[4-(trityloxy)but-2-yn-1-yl]pyrimidine-2,4(1H,3H)-dione
IC50: 0.404 mM
5-methyl-1-[4-(trityloxy)but-2-yn-1-yl]pyrimidine-2,4(1H,3H)-dione
-
IC50: 0.0031 mM
5-methyl-1-[4-(trityloxy)butyl]pyrimidine-2,4(1H,3H)-dione
IC50: 0.0033 mM
5-methyl-1-[4-(trityloxy)butyl]pyrimidine-2,4(1H,3H)-dione
-
IC50: 0.01 mM
5-[(E)-2-bromoethenyl]-2'-O-octanoyluridine
IC50: 0.006 mM
5-[(E)-2-bromoethenyl]-2'-O-octanoyluridine
-
-
6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-tritylhexanamide
IC50: 0.019 mM
6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-tritylhexanamide
-
IC50: 0.0034 mM
9-[(2Z)-4-(trityloxy)but-2-en-1-yl]-guanine
IC50: above 0.5 mM
9-[(2Z)-4-(trityloxy)but-2-en-1-yl]-guanine
-
IC50: above 0.5 mM
acyclovir
Herpes simplex virus
-
syn. 9-[(2-hydroxyethoxy)methyl]guanine
acyclovir
Herpes simplex virus
-
50% photoincorporation inhibition of wild-type enzyme at 0.05 mM, 50% photoincorporation inhibition of C336Y mutant above 0.3 mM
ADP
-
-
ATP
Herpes simplex virus
-
50% photoincorporation inhibition of wild-type enzyme at 0.15 mM, 50% photoincorporation inhibition of C336Y mutant above 1 mM
ATP
Tequatrovirus T4
-
non-competitive
Ba2+
-
-
Ba2+
Tequatrovirus T4
-
0.29 mM
Caffeine
-
competitive to ATP, 75% inhibition at 20 mM
Caffeine
-
competitive to ATP
dCTP
-
mitochondrial enzyme
dCTP
-
30-45% inhibition of mitochondrial enzyme at 0.6 or 1 mM, no inhibition of cytosolic enzyme
dCTP
-
80% inhibition of adult enzyme at 1 mM, almost no inhibition of fetal enzyme
dCTP
-
strong feedback inhibition, tight binding at the active site in stoichiometric amount
deoxcytidine
-
deoxcytidine
poor inhibitor
deoxyuridine
-
-
deoxyuridine
-
competitive to thymidine
dTDP
-
83% inhibition at 0.1 mM
dTDP
-
competitive to ATP
dTMP
-
8% inhibition at 0.1 mM
dTMP
-
competitive to ATP
dTMP
-
competitive to thymidine
dTTP
-
84% inhibition at 0.1 mM
dTTP
-
50-90% inhibition at 0.2-0.8 mM; competitive to thymidine
dTTP
-
competitive feedback inhibition
dTTP
-
strong feedback inhibition, tight binding at the active site in stoichiometric amount
dTTP
feedback inhibitor, binds tightly to the enzyme at the active site
dTTP
competitive feedback inhibition, binding structure analysis
dTTP
-
binds to the active site
dTTP
binds to the active site
dTTP
-
non-competitive with thymidine, competitive to ATP
dTTP
Tequatrovirus T4
-
inhibition dependent on pH
dTTP
-
competitive feedback inhibition, binding structure analysis
dTTP
binds to the active site
dUTP
-
-
dUTP
-
competitive to ATP
N-(2-cyanoethyl)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
IC50: 0.46 mM
N-(2-cyanoethyl)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
-
IC50: above 0.5 mM
N-(2-cyanoethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
IC50: 0.353 mM
N-(2-cyanoethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
-
IC50: above 0.5 mM
N-(2-[[cyano(phenyl)methyl]amino]-2-oxoethyl)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
IC50: 0.318 mM
N-(2-[[cyano(phenyl)methyl]amino]-2-oxoethyl)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
-
IC50: above 0.5 mM
N-(cyanomethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
IC50: 0.268 mM
N-(cyanomethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
-
IC50: above 0.5 mM
N-(diphenylmethyl)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
IC50: 0.238 mM
N-(diphenylmethyl)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
-
IC50: above 0.5 mM
N-(diphenylmethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
IC50: 0.038 mM
N-(diphenylmethyl)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
-
IC50: 0.043 mM
N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]-2,2-diphenylacetamide
IC50: 0.027 mM
N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]-2,2-diphenylacetamide
-
IC50: 0.115 mM
N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]-3-(trifluoromethyl)benzamide
IC50: 0.028 mM
N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]-3-(trifluoromethyl)benzamide
-
IC50: 0.072 mM
N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]-9H-xanthene-9-carboxamide
IC50: 0.033 mM
N-[(2Z)-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)but-2-en-1-yl]-9H-xanthene-9-carboxamide
-
IC50: 0.131 mM
N-[2-[(diphenylmethyl)amino]-2-oxoethyl]-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
IC50: 0.287 mM
N-[2-[(diphenylmethyl)amino]-2-oxoethyl]-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
-
IC50: above 0.5 mM
N-[cyano(phenyl)methyl]-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
IC50: 0.208 mM
N-[cyano(phenyl)methyl]-4-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)butanamide
-
IC50: 0.495 mM
N-[cyano(phenyl)methyl]-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
IC50: 0.075 mM
N-[cyano(phenyl)methyl]-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)hexanamide
-
IC50: 0.275 mM
N3-methyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-thymine
IC50: above 0.5 mM
N3-methyl-1-[(2Z)-4-(trityloxy)but-2-en-1-yl]-thymine
-
IC50: above 0.5 mM
penciclovir
-
penciclovir
-
three PCV-resistant FHV-1 variants selected in vitro carry mutations in the TK gene. Penciclovir is a potent selective inhibitor of Feline herpesvirus-1. The virus-encoded thymidine kinase is an important determinant of the virus susceptibility to nucleoside analogues
suramin
-
-
thymidine
Herpes simplex virus
-
50% photoincorporation inhibition of wild-type enzyme at 0.003 mM, 50% photoincorporation inhibition of C336Y mutant at 0.05 mM
thymidine
inhibition of deoxycytidine kinase activity
TTP
-
-
TTP
-
83% inhibition at 1 mM, 43% inhibition at 0.1 mM, 15% inhibition at 0.01 mM
Zn2+
-
-
Zn2+
Tequatrovirus T4
-
1.1 mM and 2.9 mM
additional information
not inhibited by D-5-(bromovinyl)-2'-deoxyuridine, L-5-(bromovinyl)-2'-deoxyuridine, and 2-phenylamino-9-(4-hydroxybutyl)-6-oxopurine
-
additional information
-
not inhibited by D-5-(bromovinyl)-2'-deoxyuridine, L-5-(bromovinyl)-2'-deoxyuridine, and 2-phenylamino-9-(4-hydroxybutyl)-6-oxopurine
-
additional information
-
no inhibition: phenylmethylsulfonylfluoride
-
additional information
-
overview: deoxythymidine analogs
-
additional information
Herpes simplex virus
-
structural requirements of bromine substituted 5-heteroaromatic 2'-deoxyuridines as antiviral agents
-
additional information
Herpes simplex virus
-
synthesis of tricarbonyl rhenium and technetium complexes of a 5-carboxamide 5-ethyl-2'-deoxyuridine for selective inhibition of herpes simplex virus thymidine kinase
-
additional information
-
bisubstrate analogs with adenosine and thymidine joined at their 5' positions by polyphorphoryl linkages of varying lengths can serve as inhibitors
-
additional information
-
overview: purine nucleotides, pyrimidine nucleotides
-
additional information
-
no inhibition: AMP, CMP, GMP, putrescine, spermine, spermidine
-
additional information
-
5'-derivatives of thymidine
-
additional information
-
inhibition potency of dNTPs in descending order: dTTP, dCTP, dATP, inhibitor binding structurally stabilizes the enzyme, induction of conformational changes upon ligand binding, overview
-
additional information
-
at physiological relevant concentration deoxycytidine phosphorylation is not inhibited by 3-azido-3'-deoxythmidine or 3'-fluorothymidine
-
additional information
-
5'-derivatives of thymidine
-
additional information
-
structure-aided design of a series of substituted 3'- or 5'-thiourea derivatives of beta- and alpha-thymidine, respectively, as thymidine monophosphate kinase inhibitors
-
additional information
-
at physiological relevant concentration deoxycytidine phosphorylation is not inhibited by 3'-azido-3'-deoxythmidine or 3'-fluorothymidine
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.